THE FUSE

At this time of year, when the dark shadow of depression affects many in the global north and New Year’s resolutions abound with promises to eat healthy, exercise more, and be nicer to our family and friends, the fact is that most of us will fail and continue to behave exactly like we did in 2025. Even as new GLP-1 agonists with brand names like Wegovy and Zepbound make it easier to achieve weight loss, and selective serotonin reuptake inhibitors (SSRIs) like Prozac and Zoloft provide a hedge against depression, there is growing interest in an old idea: psychedelics.